Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
March 03 2022 - 4:31PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”)
today announced that members of the executive management team will
give corporate presentations at two upcoming investor conferences
including:
- Cowen 42nd Annual Virtual Healthcare Conference corporate
presentation on Wednesday, March 9, 2022 at 2:50 p.m. ET. Link
here
- Oppenheimer’s 32nd Annual Healthcare Conference corporate
presentation on Wed, March 16, 2022 at 1:20 p.m. ET. Link here
To participate in the audio webcast, interested parties can
access the live webcast under "News/Events” through the “Investors”
section of the Aurinia corporate website at
www.auriniapharma.com.
ABOUT AURINIA
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations that are impacted by serious diseases with a high unmet
medical need. In January 2021, the Company introduced LUPKYNIS™
(voclosporin), the first FDA-approved oral therapy for the
treatment of adult patients with active lupus nephritis (LN). The
Company’s head office is in Victoria, British Columbia, its U.S.
commercial hub is in Rockville, Maryland, and the Company focuses
its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220303005982/en/
Investor and Media: Dana Lynch Investor Relations and
Corporate Communications dlynch@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024